| Thanks
to Lead SoCalBio Sponsors
|
 |
|
Take
Advantage of SoCalBio's Group
Purchasing Program to Cut the Cost of Doing
Business
Vendor
Showcase
For Translation Services
|
Looking
for Legal Help with IP, Business,
Labor and Immigration
Matters?
|
|
|
Join
SoCalBio
Join well-known entrepreneur Alfred
Mann and other SoCalBio leaders to promote
the biotech and device industries in the
Greater Los Angeles Metro Area for job
creation and overall economic growth.
|
 |
|
|
| RSVP
Now (Only 17 Days Away) |
|
|
| Conference
Highlight |
|
11th SoCalBio
Investor Conference Offers Three Breakouts on
Corporate Partnerships
 Emerging
biotech, nanotech and medical device firms
attending the
11th SoCalBio Investor conference held on
September 17 will
learn "insider" strategies for
forging and maintaining corporate
partnerships as a source of funding.
Conference sponsors, Reed
Smith, Ernst
& Young and Bingham,
will each lead a breakout with participation
of local firms, such as Edwards Lifesciences
and Beckman Coulter, and established
players, such as Merck and Pfizer, on:
- The importance of partnerships as a
source of funding in a changing
bioscience industry landscape,
- What to learn from recent device
corporate alliances, and
- Lessons derived from biopharma
partnership deals.
Also See:
|
| Apply
Now to Make a Presentation at the SoCalBio
Investor/Partnership Conference |
Is
your firm an innovative advanced medical
technology or biotech company interested in
raising capital, partnering your products or
technologies, or initiating strategic
alliances? If so, apply now for a company
presentation slot during the 11th SoCalBio
Investor and Partnership Conference on Sep.
17, 2009 at the Loews Hotel in Santa Monica. Send
an executive summary
28 Companies
Selected to Date to Make presentations
during the SoCalBio Conference on September
17
-
Allvivo Vascular
-
APOImmune
-
Applied Biocode
-
BioSeven
-
Biotic
Labs
-
Cardiopolymers
-
CytomX Therapeutics
-
DxTerity
Diagnostics
-
Fibron
-
iCo
Therapeutics
|
-
ImaginAB
-
ImmunGene
-
Inscent
-
K-Space
-
Kineta
-
Lerner
Medical Devices
-
Med
BioGene
-
MiCardia
-
preSage
Biosciences
|
|
|
|
Upcoming SoCalBio Business
Mixers
|
- September
30, 4:00 - 7:00 pm
-
 SoCalBio
Networking Forum in Ventura County
(Westlake Village Inn)
Focus: Innovation
and Protecting Your Intellectual Property
in a Changing Patent Regime ... More
Info
Focus: Why
Bioscience Companies Should Care About
Social Media ... More
Info
|
| New
SoCalBio Members |
|
 Replenish,
Inc.
(Pasadena)
Co-founded by
Sean Caffey, MD (photo right), Replenish is
a medical device firm developing an intraocular
drug delivery micro-pump to deliver the
right amount of medications for eye problems
such as glaucoma and age-related macular
degeneration... Learn
more
 Reshape
Medical
(San
Clemente)
A
development-stage medical device
manufacturer focused on the development of
non-surgical weight loss devices. The
company's main product is an intragastric
balloon that can be used as aids in the
treatment of obese or overweight
patients.... Learn
more
 Jinn
Su, Patent Attorney
Jinn Su
(photo right) is a patent attorney trained
in both engineering and the law. He works
with companies to protect their inventions
in the medical device, software, and
semiconductor fields ... Learn
more
|
| Company
Profile |
|
ImmunoCellular
Therapeutics (Woodland Hills)
Taking
Aim at the Root Cause of Cancer
 Led
by Dr. Manish Singh (photo right)
ImmunoCellular Therapeutics (IMUC.OB) is an
emerging cancer immunotherapy company
headquartered in the San Fernando Valley.
The company is developing therapeutic and
diagnostic product candidates taking aim at
the root cause of the disease, cancer stem
cells (CSCs), based on two distinct
technology platforms - active (cancer
vaccines) and passive (monoclonal antibodies
or mAbs). This approach is in the early
stages of development, but has the potential
to become a disruptive, paradigm shifting
therapeutic approach to the treatment of
cancer.... Learn
more
|
| Financing |
|
ValenTx
Inc. (Carpinteria)
ValenTx -- a developer of minimally-invasive
treatments for morbid obesity -- has raised
$20.29 million in new VC funding, according
to a regulatory filing. The company
previously raised around $7 million from
firms like EDF Ventures, Affinity Capital
Management, Kaiser Permanente Ventures, TGap
Ventures and Sapient Capital Management
.... Learn
more
AVANIR
(Irvine)
The company announced last week that it had
raised gross proceeds of approximately $10.6
million via the sale of approximately 4.5
million shares of common stock at a weighted
average price of $2.34 per share. The shares
were sold into the open market at prevailing
prices through the Company's Controlled
Equity Offering facility... Learn
more
CNS
Response (Costa Mesa)
Company announced last week that it had
completed a closing of its private
placement, resulting in gross proceeds to
the Company of approximately $2,000,000.
Proceeds from the transaction will be used
for general corporate purposes, including
clinical trial expenses, research and
development expenses, and general and
administrative expenses.... Learn
more
|
| Clinical
Studies |
|
Valeant's
retigabine fails in shingles pain study
The trial was designed to evaluate
retigabine as a treatment for post-shingles
pain, and was intended to help Valeant find
the most effective dose of the drug. But the
company said the drug was not as effective
as it expected ... Learn
more
ISTA
says daily Xibrom eye drops met goal in
study
The company said Xibrom QD eye drops were
significantly better than a placebo at
eliminating eye inflammation 15 days after
cataract surgery. The drug also achieved a
secondary goal of eliminating eye pain one
day after surgery. The drug is a
once-per-day version of Xibrom, a drug that
is already on the market but is intended to
be used twice a day... Learn
more
|
| Product
Approval |
|
Watson
Pharmaceuticals (Corona)
Company gets approval for its
over-the-counter version of the emergency
contraceptive Plan B, which is made by Barr
Pharmaceuticals unit Duramed. Watson will
call its version Next Choice. It is meant to
be taken within 72 hours of unprotected
intercourse to reduce the chance of
pregnancy... Learn
more
|
|
About SoCalBio
|
 SoCalBio
membership links you to partners, contract
manufacturers, regulatory and legal experts,
and policy makers. The organization's
programs help emerging biotech and medical
device companies grow. Membership is
affordable -- as low as $500 -- and offers
access to networking opportunities,
advocacy, discounts through our group
purchasing program group
purchasing program and
other benefits you simply can't find
elsewhere ... Join
SoCalBio
|
|
|
Editor:
